Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects

McMaster University

$75,750.00

Microfluidic high-throughput screening device for C. elegans movement based assays

EF 2011-12

Résumé
C. elegans is one of the most widely studied organisms that is of great importance in the study of molecular mechanisms underlying numerous biological and disease processes. Because C. elegans carries more than half of human disease genes and utilizes many of the same mechanisms, the findings in this model can be successfully translated to humans. Furthermore, due to its small size (~1 mm, ~1,000 somatic cells), short generation time (~2.5 days), and transparent body, C. elegans (worms) serves as an ideal laboratory model for understanding the role of human genes in diseases as well as an effective screen to determine the effect of drug candidates in mitigating these diseases. However, current methods of screening worms involve observation of their movement and imaging them following exposure to chemicals. These methods are qualitative, labor-intensive prone to human errors, time consuming, costly and not amenable to high throughput. Automation, standardization and parallelization of screening processes for model organisms is crucial in lowering their cost and enabling their widespread use in drug discovery. We propose to take a novel approach to develop microfluidic devices to study the response of worms to various chemicals. This is based on our recent promising discovery that C. elegans respond to electrical signals and move in a directed manner inside microfluidic channels. This discovery has allowed us, for the first time, to induce movement behaviour on demand and quantitatively measure its response. Here we propose to combine electric stimuli based movement response of the worms with microfabrication and microfluidic technology to develop devices that will screen for drug candidates for Parkinson's disease in a high throughput manner. The successful outcome of this project will be a low cost device that can be used by biologist and pharmaceutical researchers for drug candidate screening using animal models for Parkinson's disease. The technology developed can also be applied with suitable modifications for any movement based disorders, neurological diseases and even obesity and hypertension if expressed in C.elegans.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
399261-2011
Name nom
Selvaganapathy, Ponnambalam
Department département
Mechanical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2011
Award amount
75750
Program id
CHRPJ
Program nane en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
515
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Instrumentation technology
Area of application fr
Technologie de l'instrumentation
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Partie
1
Nb partie
3
Application title
Microfluidic high-throughput screening device for C. elegans movement based assays
Keyword
NSERC
Application summary
C. elegans is one of the most widely studied organisms that is of great importance in the study of molecular mechanisms underlying numerous biological and disease processes. Because C. elegans carries more than half of human disease genes and utilizes many of the same mechanisms, the findings in this model can be successfully translated to humans. Furthermore, due to its small size (~1 mm, ~1,000 somatic cells), short generation time (~2.5 days), and transparent body, C. elegans (worms) serves as an ideal laboratory model for understanding the role of human genes in diseases as well as an effective screen to determine the effect of drug candidates in mitigating these diseases. However, current methods of screening worms involve observation of their movement and imaging them following exposure to chemicals. These methods are qualitative, labor-intensive prone to human errors, time consuming, costly and not amenable to high throughput. Automation, standardization and parallelization of screening processes for model organisms is crucial in lowering their cost and enabling their widespread use in drug discovery. We propose to take a novel approach to develop microfluidic devices to study the response of worms to various chemicals. This is based on our recent promising discovery that C. elegans respond to electrical signals and move in a directed manner inside microfluidic channels. This discovery has allowed us, for the first time, to induce movement behaviour on demand and quantitatively measure its response. Here we propose to combine electric stimuli based movement response of the worms with microfabrication and microfluidic technology to develop devices that will screen for drug candidates for Parkinson's disease in a high throughput manner. The successful outcome of this project will be a low cost device that can be used by biologist and pharmaceutical researchers for drug candidate screening using animal models for Parkinson's disease. The technology developed can also be applied with suitable modifications for any movement based disorders, neurological diseases and even obesity and hypertension if expressed in C.elegans.